Prognostic Role of TP53 Variants in the Phase III Study of FOLFIRI/cetuximab Versus FOLFIRI/cetuximab Followed by Cetuximab (cet) Alone in First-Line Therapy of Patients with RAS and BRAF Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) (ERMES Study).
JOURNAL OF CLINICAL ONCOLOGY(2023)
关键词
EGFR Mutations
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要